Logo do repositório
 
Publicação

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

2023-07Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorCibula, David
dc.contributor.authorRosaria Raspollini, Maria
dc.contributor.authorPlanchamp, François
dc.contributor.authorCenteno, Carlos
dc.contributor.authorChargari, Cyrus
dc.contributor.authorFelix, Ana
dc.contributor.authorFelix, Ana
dc.contributor.authorFischerová, Daniela
dc.contributor.authorJahnn-Kuch, Daniela
dc.contributor.authorJoly, Florence
dc.contributor.authorKohler, Christhardt
dc.contributor.authorLax, Sigurd
dc.contributor.authorLorusso, Domenica
dc.contributor.authorMahantshetty, Umesh
dc.contributor.authorMathevet, Patrice
dc.contributor.authorRaj Naik, Mr
dc.contributor.authorNout, Remi A.
dc.contributor.authorOaknin, Ana
dc.contributor.authorPeccatori, Fedro
dc.contributor.authorPersson, Jan
dc.contributor.authorQuerleu, Denis
dc.contributor.authorRubio Bernabé, Sandra
dc.contributor.authorSchmid, Maximilian P.
dc.contributor.authorStepanyan, Artem
dc.contributor.authorSvintsitskyi, Valentyn
dc.contributor.authorTamussino, Karl
dc.contributor.authorZapardiel, Ignacio
dc.contributor.authorLindegaard, Jacob
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblElsevier Science B.V., Amsterdam.
dc.date.accessioned2023-07-21T22:21:20Z
dc.date.available2023-07-21T22:21:20Z
dc.date.issued2023-07
dc.descriptionFunding Information: The authors thank ESGO, ESTRO, and ESP for their support. The authors also thank the 155 international reviewers (physicians and patient representatives, see Appendix 2 in Online Supplemental File 2) for their valuable comments and suggestions. The authors thank the ESGO office, especially Kamila Macku, Tereza Cicakova, and Kateřina Šibravová, provided invaluable logistical and administrative support throughout the process. The development group (including all authors) is collectively responsible for the decision to submit for publication. DC (chair), JL (chair), MRR (chair) and FP (methodologist) wrote the first draft of the manuscript. All other contributors have actively given personal input, reviewed the manuscript, and have given final approval before submission. DC is responsible for the overall content as the guarantor. Initiated through the ESGO the decision to develop multidisciplinary guidelines was made jointly by the ESGO, ESTRO, and ESP. The ESGO provided administrative support. The ESGO, ESTRO and ESP are nonprofit knowledgeable societies. *These guidelines were developed by ESGO, ESTRO and ESP and are published in the Int J Gynecol Cancer, Radiother Oncol and Virchows Archiv. CCh has reported advisory boards for GSK, MSD and EISAI; SFL has reported advisory boards for MSD, GSK, AstraZeneca and Novartis; DL has reported consultant honoria from AstraZeneca, Clovis Oncology, GSK, MSD, Immunogen, Genmab, Amgen, Seagen and PharmaMar, advisory boards for AstraZeneca, Merck Serono, Seagen, Immunogen, Genmab, Oncoinvest, Corcept and Sutro, research institutional funding from Clovis Oncology, GSK, MSD and PharmaMar, research sponsored by AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, Incyte, MSD, Roche, Seagen and Novartis, and speakers’ bureau activities for AstraZeneca, Clovis Oncology, GSK, MSD and PharmaMar; UM has reported advisory boards for AstraZeneca (Steering committee member for CALLA Study); RN has reported research grants from Elekta, Varian, Accuray, Dutch Research Council, and Dutch Cancer Society; AO has reported personal fees for advisory board membersip from Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, EMD Serono, F. Hoffmann-La Roche, Genmab/Seagen, GSK, ImmunoGen, Itheos, Merck Sharp & Dohme de Espana, SA, Mersana Thereapeutics, Novocure, PharmaMar, piIME Oncology, Roche, Sattucklabs, Sutro Biopharma and Tesaro, and personal fees for travel/accomodation from AstraZeneca, PharmaMar and Roche; DQ has reported advisory boards for Mimark inc; MPS has reported research grants and personal fees for workshops from Elekta AB; DC, MRR, FP, CC, AF, DF, DJK, FJ, CK, PM, RN, FPec, JP, SR, AS, VS, KT, IZ and JCL have reported no conflicts of interest. Not commissioned; internally peer reviewed. Not applicable. Not applicable. David Cibula, Maria Rosaria Raspollini, François Planchamp, Carlos Centeno, Cyrus Chargari, Ana Felix, Daniela Fischerova, Daniela Jahn-Kuch, Florence Joly, Christhardt Kohler, Sigurd F. Lax, Domenica Lorusso, Umesh Mahantshetty, Patrice Mathevet, Raj Naik, Remi Nout, Ana Oaknin, Fedro Peccatori, Jan Persson, Denis Querleu, Sandra Rubio, Maximilian Paul Schmid, Artem Stepanyan, Valentyn Svintsitskyi, Karl Tamussino, Ignacio Zapardiel, Jacob Christian Lindegaard. All data relevant to the study are included in the article or uploaded as supplementary information. Funding Information: CCh has reported advisory boards for GSK, MSD and EISAI; SFL has reported advisory boards for MSD, GSK, AstraZeneca and Novartis; DL has reported consultant honoria from AstraZeneca, Clovis Oncology, GSK, MSD, Immunogen, Genmab, Amgen, Seagen and PharmaMar, advisory boards for AstraZeneca, Merck Serono, Seagen, Immunogen, Genmab, Oncoinvest, Corcept and Sutro, research institutional funding from Clovis Oncology, GSK, MSD and PharmaMar, research sponsored by AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, Incyte, MSD, Roche, Seagen and Novartis, and speakers’ bureau activities for AstraZeneca, Clovis Oncology, GSK, MSD and PharmaMar; UM has reported advisory boards for AstraZeneca (Steering committee member for CALLA Study); RN has reported research grants from Elekta, Varian, Accuray, Dutch Research Council, and Dutch Cancer Society; AO has reported personal fees for advisory board membersip from Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, EMD Serono, F. Hoffmann-La Roche, Genmab/Seagen, GSK, ImmunoGen, Itheos, Merck Sharp & Dohme de Espana, SA, Mersana Thereapeutics, Novocure, PharmaMar, piIME Oncology, Roche, Sattucklabs, Sutro Biopharma and Tesaro, and personal fees for travel/accomodation from AstraZeneca, PharmaMar and Roche; DQ has reported advisory boards for Mimark inc; MPS has reported research grants and personal fees for workshops from Elekta AB; DC, MRR, FP, CC, AF, DF, DJK, FJ, CK, PM, RN, FPec, JP, SR, AS, VS, KT, IZ and JCL have reported no conflicts of interest. Publisher Copyright: © 2023 ESGO, ESTRO, ESP
dc.description.abstractIn 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer. Given the large body of new evidence addressing the management of cervical cancer, the three sister societies jointly decided to update these evidence-based guidelines. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment in cervical cancer. To serve on the expert panel (27 experts across Europe) ESGO/ESTRO/ESP nominated practicing clinicians who are involved in managing patients with cervical cancer and have demonstrated leadership through their expertise in clinical care and research, national and international engagement, profile, and dedication to the topics addressed. To ensure the statements were evidence based, new data identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Before publication, the guidelines were reviewed by 155 independent international practitioners in cancer care delivery and patient representatives. These updated guidelines are comprehensive and cover staging, management, follow-up, long-term survivorship, quality of life and palliative care. Management includes fertility sparing treatment, early and locally advanced cervical cancer, invasive cervical cancer diagnosed on a simple hysterectomy specimen, cervical cancer in pregnancy, rare tumors, recurrent and metastatic diseases. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent3865361
dc.identifier.doi10.1016/j.radonc.2023.109682
dc.identifier.issn0167-8140
dc.identifier.otherPURE: 66904863
dc.identifier.otherPURE UUID: 04ebd13d-3042-40df-b6b8-0ca8da0f8615
dc.identifier.otherScopus: 85162178928
dc.identifier.otherPubMed: 37336614
dc.identifier.otherORCID: /0000-0002-2653-2262/work/151417761
dc.identifier.urihttp://hdl.handle.net/10362/155687
dc.identifier.urlhttps://www.scopus.com/pages/publications/85162178928
dc.language.isoeng
dc.peerreviewedyes
dc.subjectCervical Cancer
dc.subjectPathology
dc.subjectRadiation
dc.subjectSurgical Oncology
dc.subjectHematology
dc.subjectOncology
dc.subjectRadiology Nuclear Medicine and imaging
dc.subjectSDG 3 - Good Health and Well-being
dc.titleESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023en
dc.typejournal article
degois.publication.titleRadiotherapy And Oncology
degois.publication.volume184
dspace.entity.typePublication
person.familyNameFelix
person.givenNameAna
person.identifier.ciencia-idA617-A56B-6FC6
person.identifier.orcid0000-0002-2653-2262
person.identifier.scopus-author-id55574221034
rcaap.rightsopenAccess
relation.isAuthorOfPublicatione267d7fd-7e65-4533-9f0a-6fceabcf4b7b
relation.isAuthorOfPublication.latestForDiscoverye267d7fd-7e65-4533-9f0a-6fceabcf4b7b

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1_s2.0_S0167814023002207_main.pdf
Tamanho:
3.69 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica